Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring

Therapeutic Drug Monitoring

Volumn 33, Issue 1, 2011, Pages 86-93

  Hassan, Arwa ^a   Burhenne, Jürgen ^a   Riedel, Klaus Dieter ^a   Weiss, Johanna ^a   Mikus, Gerd ^a   Haefeli, Walter E ^a   Czock, David ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

nonadherence; pharmacokinetics; therapeutic drug monitoring; ultrarapid metabolizer; voriconazole

Indexed keywords

CYTOCHROME P450 2C19; VORICONAZOLE;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG METABOLISM; DRUG MONITORING; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TANDEM MASS SPECTROMETRY; TREATMENT REFUSAL;

ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; FEMALE; GENOTYPE; HUMANS; MALE; MEDICATION ADHERENCE; POLYMORPHISM, GENETIC; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES;

EID: 78751642763     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31820530cd     Document Type: Article

References (32)

1. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit. 2008;30:167-172.
2. Hyland R, Jones BC, Smith DA. Identification of the cytochrome p450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 2003;31:540-547.
3. Roffey SJ, Cole S, Comby P, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos. 2003; 31:540-547.
4. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-211.
5. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53:24-34.
6. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48:2166-2172.
7. Lazarus HM, Blumer JL, Yanovich S, et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol. 2002;42:393-400.
8. Rengelshausen J, Banfield M, Riedel K-D, et al. Opposite effects of short-term and long-term St John's Wort intake on voriconazole pharmacoki-netics. Clin Pharmacol Ther. 2005;78:25-33.
9. Mikus G, Schöwel V, Drzewinska M, et al. Potent cytochrome 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther. 2006;80:126-135.
10. Geist MJ, Egerer G, Burhenne J, et al. Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications. Antimicrob Agents Chemother. 2007; 51:3455-3456.
11. Hafner V, Albermann N, Haefeli WE, et al. Inhibition of voriconazole metabolism by chloramphenicol in an adolescent with CNS aspergillosis. Antimicrob Agents Chemother. 2008;52:4172-4174.
12. Weiss J, Ten Hoevel MM, Burhenne J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voricona-zole. J Clin Pharmacol. 2009;49:196-204.
13. Rudberg I, Mohebi B, Hermann M, et al. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther. 2008;83:322-327.
14. Lennard L, Welch J, Lilleyman JS. Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance? Br J Cancer. 1995;72:1004-1006.
15. Holt DW, Tucker GT, Jackson PR, et al. Amiodarone pharmacokinetics. Am Heart J. 1983;106:840-847.
16. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J. 2002;21:240-248.
17. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007;109:1532-1535.
18. Scholz I, Oberwittler H, Riedel K-D, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009;68:906-915.
19. Pennick GJ, Clark M, Sutton DA, et al. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother. 2003;47:2348-2350.
20. Hafner V, Czock D, Burhenne J, et al. Pharmacokinetics of sulfobuty-lether-beta-cyclodextrin (SBECD) and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodialfiltration. Antimicrob Agents Chemother. 2010; 54:2596-2602.
21. Stopher DA, Gage R. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. Chromatogr B Biomed Sci Appl. 1997;691:441-448.
22. Baldwin RM, Ohlsson S, Pedersen RS, et al. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol. 2008;65:767-777.
23. Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50:27-36.
24. Levêque D, Nivoix Y, Jehl F, et al. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents. 2006;27:274-284.
25. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-362.
26. Pedersen RS, Brasch-Andersen C, Sim SC, et al. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol. July 28, 2010 [Epub ahead of print].
27. Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. Postgrad Med. 2010;122:184-191.
28. Stepansky MA, Roache CR, Holmbeck GN, et al. Medical adherence in young adolescents with spina bifida: longitudinal associations with family functioning. J Pediatr Psychol. 2010;35:167-176.
29. Lemanek K. Adherence issues in the medical management of asthma. J Pediatr Psychol. 1990;15:437-458.
30. Li-Wan-Po A, Girard T, Farndon P, et al. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol. 2010;69:222-230.
31. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79:103-113.
32. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacody-namic profile of voriconazole. Clin Pharmacokinet. 2006;45:649-663.